Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RiboBio
Guangzhou, Guangdong, Chinaribobio.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
RiboBio is Asia’s largest oligonucleotide-based API manufacturer, supporting projects from pre-clinical through Phase 1, Phase 2, Phase 3 to GMP and commercial manufacturing; clinical results are customer dependent and not disclosed, as RiboBio serves as a CDMO/CRO partner, rather than directly running drug trials.[1][2][3]
- Modalities
- OligonucleotideAntisense oligonucleotideSmall interfering RNAAptamermRNA-based drugs
- Industry
- Contract Manufacturing Organization
Beyond the preview
Go deeper on RiboBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RiboBio.